Structure Therapeutics, Inc. Sponsored ADR (GPCR)
NASDAQ:GPCR
Want to see GPCR full AI Analyst Report?
GPCR Stock Chart & Stats
$50.75
-$0.32(-1.18%)
At close: 4:00 PM EST
$50.75
-$0.32(-1.18%)
Day’s Range― - ―
52-Week Range$15.80 - $94.90
Previous CloseN/A
Volume219.80K
Average Volume (3M)753.26K
Market Cap
$3.16B
Enterprise Value$2.28B
Total Cash (Recent Filing)$1.46B
Total Debt (Recent Filing)$5.79M
Price to Earnings (P/E)―
Beta1.00
Next Earnings
Aug 06, 2026EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.64
Shares Outstanding71,074,520
10 Day Avg. Volume948,811
30 Day Avg. Volume753,257
Financial Highlights & Ratios
PEG Ratio-11.30
Price to Book (P/B)2.72
Price to Sales (P/S)0.00
P/FCF Ratio-18.23
Enterprise Value/Market Cap0.72
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.87K
Enterprise Value/Ebitda-13.59
Forecast
1Y Price Target
$110.17Price Target Upside117.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-1.42
Revenue Forecast (FY)$33.33M
Bulls Say, Bears Say
Bulls Say
Strong Balance Sheet / Low LeverageA large equity base and negligible debt provide durable financial flexibility to fund multi-year clinical programs and absorb trial timing variability. This reduces near-term refinancing pressure and supports sustained R&D spending as the company advances late-stage assets.
Robust Phase 2b Data And Phase 3 ReadinessPeer‑reviewed Phase 2b efficacy and durable weight‑loss durability materially de‑risks the lead oral GLP‑1 program and supports regulatory/Phase 3 design. Structural clinical validation strengthens the company’s product strategy and long‑term commercial potential in obesity therapeutics.
Strengthened Operational LeadershipHiring an executive experienced in late‑stage development, commercialization and global operations improves execution capacity for Phase 3 and potential launch. Better legal and commercial leadership supports regulatory interactions and long‑term go‑to‑market readiness.
Bears Say
Pre‑revenue With Widening Operating LossesBeing pre‑revenue with growing operating losses means long‑term value depends entirely on successful clinical outcomes and commercialization. Persistent negative profitability pressures capital needs and creates execution risk if pipeline readouts disappoint or timelines slip.
High, Persistent Cash BurnMaterial and accelerating free cash outflows force ongoing capital raises to sustain development. Even with current cash, sustained burn increases dependency on external financing and constrains optionality for parallel programs, raising execution and dilution risk over the medium term.
Ongoing Dilution Risk From ATM FinancingWhile ATM expansion enhances funding flexibility, removing issuance caps structurally raises the likelihood of future equity issuance. Reliance on equity markets to fund clinical campaigns can dilute existing holders and link execution to market access rather than internal cash generation.
Structure Therapeutics, Inc. Sponsored ADR News
GPCR FAQ
What was Structure Therapeutics, Inc. Sponsored ADR’s price range in the past 12 months?
Structure Therapeutics, Inc. Sponsored ADR lowest stock price was $15.80 and its highest was $94.90 in the past 12 months.
What is Structure Therapeutics, Inc. Sponsored ADR’s market cap?
Structure Therapeutics, Inc. Sponsored ADR’s market cap is $3.16B.
When is Structure Therapeutics, Inc. Sponsored ADR’s upcoming earnings report date?
Structure Therapeutics, Inc. Sponsored ADR’s upcoming earnings report date is Aug 06, 2026 which is in 44 days.
How were Structure Therapeutics, Inc. Sponsored ADR’s earnings last quarter?
Structure Therapeutics, Inc. Sponsored ADR released its earnings results on May 07, 2026. The company reported -$0.35 earnings per share for the quarter, beating the consensus estimate of -$0.351 by $0.001.
Is Structure Therapeutics, Inc. Sponsored ADR overvalued?
According to Wall Street analysts Structure Therapeutics, Inc. Sponsored ADR’s price is currently Undervalued.
Does Structure Therapeutics, Inc. Sponsored ADR pay dividends?
Structure Therapeutics, Inc. Sponsored ADR does not currently pay dividends.
What is Structure Therapeutics, Inc. Sponsored ADR’s EPS estimate?
Structure Therapeutics, Inc. Sponsored ADR’s EPS estimate is -0.38.
How many shares outstanding does Structure Therapeutics, Inc. Sponsored ADR have?
Structure Therapeutics, Inc. Sponsored ADR has 71,074,520 shares outstanding.
What happened to Structure Therapeutics, Inc. Sponsored ADR’s price movement after its last earnings report?
Structure Therapeutics, Inc. Sponsored ADR reported an EPS of -$0.35 in its last earnings report, beating expectations of -$0.351. Following the earnings report the stock price went down -0.128%.
Which hedge fund is a major shareholder of Structure Therapeutics, Inc. Sponsored ADR?
Currently, no hedge funds are holding shares in GPCR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Structure Therapeutics, Inc. Sponsored ADR Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$110.17 (117.08% Upside)
$110.17 (117.08% Upside)
Blogger Sentiment
Bullish
GPCR Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 475.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▲ 1.3%
Last 30 Days ▼ 2.0%
Last 30 Days ▼ 2.0%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
109.43%
12-Months-Change
Fundamentals
Return on Equity
-15.14%
Trailing 12-Months
Asset Growth
74.04%
Trailing 12-Months
Company Description
Structure Therapeutics, Inc. Sponsored ADR
Structure Therapeutics Inc., an international biopharmaceutical company currently in its clinical development phase, is committed to creating and providing groundbreaking oral therapies for various chronic diseases that lack adequate treatment options. The company's primary investigational drug, GSBR-1290, is an orally administered, biased small molecule agonist designed to target the glucagon-like-peptide-1 receptor (GLP-1R). This G-protein-coupled receptor (GPCR) is a recognized and validated therapeutic target for managing both type-2 diabetes mellitus and obesity. Furthermore, Structure Therapeutics is developing other oral small molecule treatments that act on different GPCRs, addressing pulmonary and cardiovascular conditions. For example, ANPA-0073 is a biased agonist aimed at the apelin receptor, a GPCR linked to diseases like idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension. Another compound in their pipeline is LTSE-2578, an oral small molecule that acts as a lysophosphatidic acid 1 receptor antagonist, also being explored for the treatment of IPF. Established in 2016, the company was formerly known as ShouTi Inc. and is headquartered in South San Francisco, California.
GPCR Stock 12 Month Forecast
Average Price Target
$110.17
▲(117.08% Upside)
Technical Analysis
Ownership Overview
10.08% Insiders
25.01% Mutual Funds
44.57% Other Institutional Investors
18.21% Public Companies and Individual Investors